Regeneron to Showcase 36 AAAAI Abstracts, First Phase 3 Cat and Birch Allergy Data
Regeneron will present 36 abstracts at the AAAAI Annual Meeting Feb. 27–Mar. 2, including first-time Phase 3 results for novel antibody cocktails targeting FelD1 and BetV1 allergens in cat and birch allergies. New Dupixent data will detail IgE level reductions in children and real-world asthma benefits, supporting a Feb. 28 sBLA action date.
1. AAAAI Annual Meeting Highlights
Regeneron will present 36 abstracts across its immunology and inflammation portfolio at the AAAAI Annual Meeting in Philadelphia from February 27 to March 2, showcasing its latest innovations in allergy treatment and Dupixent® analyses.
2. Phase 3 Cat and Birch Allergy Trials
For the first time, Phase 3 “ocular challenge” data will be unveiled for antibody cocktails targeting FelD1 (cat) and BetV1 (birch) allergens, demonstrating reductions in ocular itch, conjunctival redness and skin prick reactivity versus placebo, with additional registration-enabling trials initiating later this year.
3. Dupixent Extended Analyses
New long-term analyses in children with atopic dermatitis will report sustained IgE reductions for common food and environmental allergens over 1.5 years, while real-world studies in uncontrolled asthma patients compare exacerbation rates and corticosteroid use against treatment escalation strategies.
4. Regulatory and Development Timeline
Late-breaking AIMS trial data in allergic fungal rhinosinusitis have supported a supplemental BLA under Priority Review with a target action date of February 28, 2026, and Regeneron plans further registration-enabling studies for its cat and birch allergy programs this year.